Navigation Links
NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
Date:6/1/2009

gression Free Survival (Months) 6.90 20.71 21.30 NR ------------------------------------------------------------------------- Median Overall Survival at 30 months (Months) 15.07 NR 25 NR ------------------------------------------------------------------------- * Statistically significant; NR = Not reached at 30 months

The response rates observed by the authors compare favorably with previous studies of cetuximab in combination with RT alone or CRT. Bonner JA et al (N. Engl J Med. 2006 Feb 9;354(6); 567-78) published on a randomized Phase III study with 424 patients comparing radiotherapy alone to radiotherapy plus cetuximab in locally-advanced squamous cell carcinoma of the head and neck, reporting a 74% ORR in the cetuximab plus radiotherapy arm. "Notwithstanding limitations in inter-study comparisons, the comparative data are reassuring," noted Dr. Leonardo Viana Nicacio, M.D., Director, Clinical Affairs for YM BioSciences.

Pfister DG et al (J Clin Oncol. 2006 Mar 1;24(7): 1072-8) presented the first study combining cetuximab with chemoradiotherapy. That 22 patient pilot Phase II study combined cetuximab with a chemoradiotherapy regimen (cisplatin 100mg/m2 d1, 22) in Stage III or IV, M0, squamous cell carcinoma patients. The population in that study was similar to the Reddy BK et al study although the chemotherapy dose intensity had slight differences in favor of the Pfister DG et al study (Table 2). The ORR in both studies were similar: 94% for cetuximab + CRT and 100% for nimotuzumab + CRT. Although the Pfister DG et al study had a longer follow-up, overall survival curves at 30 months are similar to the data in the Reddy BK et al study. The major difference between the studies is the benign toxicity profile reported with nimotuzumab. No deaths in the nimotuzumab trial were attributable to the treatment and no additional serious adverse
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
2. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
3. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
4. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
5. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL
6. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
7. NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING
8. NOTICE OF YM BIOSCIENCES CONFERENCE CALL TO DISCUSS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC COLORECTAL CANCER
9. YM BIOSCIENCES NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
10. YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER
11. YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 SoundConnect , an ... is proud to announce the strategic additions of ... their Boston, Charleston and Atlanta offices. SoundConnect’s ... demand for hosted solutions, collaboration and mobility that ... cost. , SoundConnect was founded in 2004, with ...
(Date:7/29/2014)... NASA technologists have hurdled a number of significant ... already revolutionary observing technology originally created for the ... by Principal Investigator Harvey Moseley, a scientist at ... has demonstrated that electrostatically actuated microshutter arrays ... voltage are as functional as the current ...
(Date:7/29/2014)... 2014   Sequenom, Inc. (NASDAQ: ... genetic analysis solutions, and Mayo Medical Laboratories (MML), ... the United States , have announced ... applications. "We have great appreciation for Mayo ... we welcome the opportunity to partner with the organization,s ...
(Date:7/29/2014)... Quantum Cheshire Cat: Can a particle be separated from ... Nature Communications , published the results of the first ... field, conducted by Chapman University in Orange, CA, and ... seen a cat without a grin," thought Alice in ... most curious thing I ever saw in my life!" ...
Breaking Biology Technology:SoundConnect Organization and Culture is Evolving 2Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4The quantum Cheshire cat: Scientists separate a particle from its properties 2The quantum Cheshire cat: Scientists separate a particle from its properties 3The quantum Cheshire cat: Scientists separate a particle from its properties 4
... SEATTLE, May 14 Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) management will present at the 2009 ... AM in Room 311 of Building A, Level 3. , ... BIO International Convention, ... 10:40 AM Eastern/4:40 PM Central European/7:40 AM Pacific, ...
... child,s gender with less ethically charged method at Reproductive ... RAMON, Calif., May 13 In response to growing ... of their next child, the Reproductive Science Center of ... it now is offering an alternative gender-selection technique with ...
... Dendreon Corporation (Nasdaq: DNDN ) announced today the ... shares of its common stock, which shares were offered for ... May 8, 2009, Deutsche Bank Securities Inc., acting as sole ... to purchase an additional 1,279,166 shares of common stock at ...
Cached Biology Technology:Gender-Selection Technique Embraced for Hopeful Parents 2Dendreon Announces Closing of Common Stock Offering 2Dendreon Announces Closing of Common Stock Offering 3
(Date:7/30/2014)... potential effects of climate change on the world,s ... wrong factors, according to a new paper by ... University of Queensland, and other organizations. The authors ... missing the point when it comes to climate ... change scientists focus on the "direct" threats of ...
(Date:7/30/2014)... Life Sciences Institute (SALSI), a joint venture between The ... University of Texas Health Science Center at San Antonio, ... Program. The winners, Emily Boice from UTSA and Lei ... for their project titled, "Novel engineered ferritins for tracking ... Boice and Huang,s research is focused on finding a ...
(Date:7/30/2014)... biologists, led by Clemson University associate professor Andrew S. ... will pave the way for novel anti-fouling paint for ... and industrial applications. , The team,s findings, published in ... larval stage of barnacles that attaches to a wide ... material that acts as an underwater heavy-duty adhesive. , ...
Breaking Biology News(10 mins):Conservation scientists asking wrong questions on climate change impacts on wildlife 2Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2
... San Diego State University researchers will lead a study ... The Guizhou snub-nosed monkey, often called the golden monkey. ... the National Science Foundation, student researchers from SDSU,s departments ... month to the Fanjingshan National Nature Reserve, home to ...
... efficient cars, buildings and domestic appliances to address climate change ... Research at the University of East Anglia. A report ... as much effort is being spent on developing energy supply technologies ... improving the efficiency with which energy is used. The ...
... Oct. 25, 2012 /PRNewswire-iReach/ -- New research shows that ... Maine have demonstrated improvements in health behaviors that persisted ... and rising health care costs continue to challenge employers, ... to reduce health risks and improve health behaviors. ...
Cached Biology News:SDSU researchers to study China's national treasure 2Efforts to mitigate climate change must target energy efficiency 2Efforts to mitigate climate change must target energy efficiency 3New Study Shows That Improvements in Employee Health Behaviors Persist Over Two Years 2
... Zero Blunt TOPO PCR ... fastest and easiest method ... or equal to95%) cloning ... amplified with proofreading thermostable ...
Quartz-Halogen, 100 W, High Intensity...
... The Baculovirus Expression System with ... recombinant pFastBac™ plasmids containing the polyhedrin ... to the baculovirus genome (bacmid DNA) ... E. coli cells. The recombinant bacmid ...
...
Biology Products: